Jia Liu, Medical oncologist at The Kinghorn Cancer Centre, shared on X:
“As patients receive multiple ADCs, are we measuring the right treatment effect?
As ADCs move into earlier treatment lines, sequencing, cross-resistance and cumulative toxicity increasingly complicate how we interpret efficacy.
PFS captures initial disease control. OS reflects the entire treatment journey.
The question is not just whether an ADC works, but when and what options remain afterwards.”
Title: Antibody drug conjugate efficacy: are we measuring the right treatment effect?
Authors: Jia Liu, Hao-Wen Sim
Title: Treatment effect discrepancy between progression-free survival and overall survival in antibody-drug conjugate trials for metastatic breast cancer: a meta-epidemiologic analysis
Get access
Authors: Luiz Felipe Costa de Almeida, Anelise Poluboiarinov Cappellaro, Mariana Macambira Noronha, Lucas Diniz da Conceição, Lorrany Larisse Costa Rodrigues, Luís Felipe Leite, Rodolfo Garza-Morales, Brenda Ernst, Andreia Cristina de Melo, Jessé Lopes da Silva, Paolo Tarantino, Dario Trapani, Felipe Batalini
You can also read:
